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Overall, therefore, these two papers provide a detailed picture of how two chemokine receptors cooperate in enabling the successful migration of a specific group of neural progenitors in the developing brain. And, like all important investigations, they also raise numerous issues and questions. For example, what is the significance of CXCR7-induced MAP kinase activation or other types of cell signaling ? Is such signaling important in producing CXCR7-mediated effects in addition to its scavenging function? Wang et al. (2011) demonstrate that this type of signaling occurs, but how it influences the role of CXCR7 is unclear given the phenotype produced by PTX activation in migrating neurons. In addition, the expression of CXCR7 occurs in cells outside the developing embryo, including in cancer cells, which are often viewed as cells undergoing a dysregulated form of development. Given the important role of CXCR4 signaling in the spread of cancer metastases (Teicher and Fricker 2010) , the functions of proteins like CXCR7 that can powerfully modify CXCR4 signaling are clearly of mechanistic and potentially therapeutic importance. Indeed, it is now clear that the discovery of CXCR7 has added an entirely new dimension to our understanding of how CXCR4 functions during development and beyond.
Activation of NMDA receptors during cerebral ischemia triggers signaling pathways that promote both neuronal death and survival. In this issue of Neuron, Sasaki et al. present evidence for a new endogenous survival pathway involving the kinase SIK2 and the CREB coactivator TORC1. The powerful neuroprotection conferred by this pathway has considerable translational potential for stroke therapy.
N-methyl-D-aspartate-type glutamate receptors (NMDARs) are essential for brain development and function (Citri and Malenka, 2007; Cohen and Greenberg, 2008) , but they also have a dark side, playing central roles in neuronal death during cerebral ischemia and other brain pathologies (Szydlowska and Tymianski, 2010) . Remarkably, even in such deleterious settings, NMDARs set in motion powerful molecular programs that attempt to protect neurons from the excitotoxic damage resulting from their activation. Thus, NMDAR activation enables the expression of prosurvival genes through the transcription factor cAMP-response element binding protein (CREB) (Lonze and Ginty, 2002) . Although the involvement of CREB in neuroprotection is well established (Kitagawa, 2007; Lonze and Ginty, 2002) , the molecular mechanisms by which NMDAR activation promotes CREBdependent neuronal survival, while also promoting cell death, remain poorly understood. In this issue of Neuron, Sasaki et al. (2011) shed light on the issue by identifying ischemia-induced degradation of salt-inducible kinase 2 (SIK2) as a pivotal step in the activation of CREB-dependent transcription, an effect involving dephosphorylation and nuclear import of the CREB coactivator transducer of regulated CREB activity 1 (TORC1) (Figure 1 ). The findings establish SIK2 and TORC1 as critical regulators of a novel endogenous neuroprotective pathway with significant implications for the treatment of cerebrovascular pathologies and other brain diseases linked to NMDARs.
CREB activation involves multiple signaling cascades that phosphorylate CREB to assemble a functional transcriptional complex (Lonze and Ginty, 2002) . Therefore, as they set out to investigate post-ischemic CREB-dependent transcription, Sasaki et al. first examined CREB phosphorylation at the welldescribed regulatory Ser133 using oxygen glucose deprivation (OGD) in cortical neuronal cultures, a model that recapitulates key features of ischemia-reperfusion injury. They uncovered an intriguing temporal dissociation between CREB phosphorylation and the upregulation of CRE activity, as measured using gene reporter assays, suggestive of a phosphorylationindependent mechanism of CREB activation. Consequently, they hypothesized the involvement of a recently discovered family of CREB transcriptional coactivators the TORC family of proteins (Conkright et al., 2003; Iourgenko et al., 2003) . TORCs translocate from the cytoplasm to the nucleus in response to increases in calcium and cAMP, a step that requires dephosphorylation (Bittinger et al., 2004; Screaton et al., 2004) . Once in the nucleus, TORCs bind CREB and promote CREB-dependent gene expression, an effect independent of Ser133 phosphorylation (Bittinger et al., 2004; Conkright et al., 2003) . Sasaki et al. (2011) found that, after OGD, TORC1 is dephosphorylated and translocated to the nucleus with a temporal profile that fits well with the upregulation of CRE activity. Using constitutively active or dominant-negative constructs, they provided convincing evidence that TORC1 upregulation or downregulation is causally linked to CREBdependent gene expression and neuronal survival after OGD. Although TORC1 has already been implicated in other CREBdependent neuronal functions, such as synaptic plasticity (Kovacs et al., 2007; Zhou et al., 2006) , the findings of Sasaki et al. (2011) establish for the first time the involvement of TORC1-CREB in an intrinsic cell survival program triggered by hypoxia-ischemia.
While dephosphorylation is necessary for its nuclear translocation, phosphorylation can sequester TORC in the cytoplasm (Screaton et al., 2004) . To begin to unravel the factors regulating TORC phosphorylation during OGD, Sasaki et al. (2011) focused on AMPK, SIK1, and SIK2, kinases known to phosphorylate TORC. They observed that SIK2 was enriched in neurons and that its levels did not change during OGD, much like CRE activity. However, SIK2 levels were markedly reduced after OGD in parallel with the increase in CRE activity and TORC1 dephosphorylation and nuclear translocation. AMPK and SIK1 did not exhibit such temporal associations with TORC1 and CRE activity. These observations raised the possibility that SIK2 regulates CREB-dependent transcription through an effect on TORC1 phosphorylation and nuclear translocation. Consistent with this hypothesis, overexpression of a constitutively active SIK2 suppressed OGD-induced CRE activity and 
SIK2 Degradation Provides Neuroprotection after Ischemia
According to Sasaki et al., ischemic neurons utilize a previously unrecognized cytoprotective pathway involving CREB activation through CaMK I/IV, SIK2, and TORC1 (left), which attempts to counterbalance the deleterious consequences of NMDAR overactivation (right). increased cell death, whereas an inactive SIK2 was neuroprotective. Similarly, RNAi downregulation or pharmacological inhibition of SIK2 increased CRE activity and neuronal survival. The demonstration that SIK2 overexpression reduced CRE activity in cells cotransfected with a wild-type (WT) TORC1 construct, but was unable to do so in the presence of a phosphorylation-resistant mutant of TORC1, clearly established that these effects of SIK2 were mediated by TORC1 phosphorylation.
Next, the authors set out to investigate the upstream mechanisms by which OGD modulates SIK2 levels and CREB transcriptional activity. After identifying CaMK I/IV as potential upstream mediators of TORC1-CREB activation, the authors explored how CaMK I/IV activity could lead to the reduction in SIK2 levels induced by OGD. They found that overexpression of dominant-negative CaMK I or CaMK IV constructs prevents the OGDinduced downregulation of SIK2. In addition, SIK2 degradation was associated with an increase in the phosphorylation of a specific SIK2 residue (Thr484). The importance of this site for SIK2 degradation was demonstrated by the fact that a phosphorylation-resistant Thr484 did not result in SIK2 degradation. In contrast, phosphorylation of Ser587, a SIK2 site also known to negatively regulate TORC phosphorylation (Katoh et al., 2006) , did not impact SIK2 protein levels. In support of this conclusion, OGD increased SIK2 Thr484 phosphorylation, but not Ser587 phosphorylation, suggesting that Thr484, but not Ser587, is an important target of CaMK I/IV-dependent SIK2 degradation. Sasaki et al. (2011) Sasaki et al. (2011) provide extensive evidence in support of SIK2 as a major determinant of neuronal survival by its regulation of CREB-induced gene expression through a TORC1-dependent mechanism. These results advance the current understanding of CREB activation in the context of neuronal survival. Although CREB phosphorylation has long been linked to CREB activation in various aspects of neuronal function, including neuroprotection (Lonze and Ginty, 2002) , this study highlights the functional relevance of an alternative mechanism present in neurons that activates CREB. Given the complexity of neuronal CREB activation, future studies could be aimed at further elucidating the mechanisms regulating TORC1. For example, synaptic activity can simultaneously activate a number of signaling cascades that lead to CREB-dependent gene expression (Cohen and Greenberg, 2008) . Understanding the contribution of each of these different pathways to TORC1 activation may help unravel the biological advantage conferred by utilizing multiple means to promote the expression of CREB-dependent genes. Moreover, addressing the signaling events involved in the dephosphorylation of TORC1 and SIK2 may also reveal new regulatory mechanisms. Because the signaling pathways described in this study were demonstrated to be downstream of synaptic NMDARs, these findings are highly relevant to other neural functions involving NMDAR-induced gene expression and to pathological states mediated by these receptors. In addition, the attenuation in TNF observed in sik2 À/À mice raises the possibility that SIK2 is also involved in post-ischemic inflammation.
Further studies exploring the mechanisms underlying this effect would be of interest because they might unveil a previously unrecognized link between SIK proteins and inflammatory signaling. The findings of the present study are particularly relevant to the pathobiology of cerebral ischemia-reperfusion and to strategies to protect the brain from the devastating consequences of ischemic stroke. Treatments targeting the NMDARs and other pathogenic factors in the ischemic cascade have not been successful in stroke clinical trials (Ginsberg, 2009 ). While the issues surrounding these disappointing results are still being debated, it has also become clear that therapeutic approaches mimicking endogenous neuroprotective strategies have a great translational potential, but are relatively unexplored (Moskowitz et al., 2010) . By identifying and characterizing a series of novel mediators in a critical, yet poorly understood, neuroprotective signaling cascade (Figure 1) , Sasaki et al. (2011) have provided valuable insight into new targets for therapeutic ischemic stroke and other pathologies involving NMDARs. Therapeutic approaches targeting the SIK2-TORC1-CREB pathway using small molecules or other clinically applicable pharmacological tools have great potential for stroke treatment and are eagerly awaited.
Heterodimerization of G protein-coupled receptors has become increasingly recognized as a valuable mechanism to increase receptor diversity. Heterodimers have been observed in the opioid receptor family, but one of the most intriguing is that formed between m-opioid and d-opioid receptors. In this issue of Neuron, He et al. present evidence further implicating these heterodimers in morphine tolerance.
Understanding opioid tolerance has long been a goal in the opioid field. Recent years have revealed many new and exciting observations regarding the underlying the processes. These involve many different and unrelated mechanisms, making the integration of these pathways very difficult. Opioid tolerance is the diminished response seen with chronic administration of a drug or, put another way, the need to progressively increase drug doses to maintain a response. Tolerance is the final common pathway for a wide range of divergent mechanisms, much like a tug of war with many different people pulling on the same rope. Each is contributing to the final effort and the loss of any one of them can have a similar effect. In this issue of Neuron, He et al. (2011) describe results that support the concept that one aspect of tolerance is mediated through m/d heterodimers and present a mechanism explaining the ability of d-opioid receptor (DOR) antagonists to prevent tolerance to morphine.
Morphine tolerance involves many distinct systems and can be influenced in many ways. The first was put forward by Collier (1980) , who proposed what he referred to as a ''hypertrophy of the cyclic AMP system.'' This was followed by the identification of the role of other neurotransmitter systems, as illustrated by the loss of morphine tolerance with blockade of the N-methyl-D-aspartate (NMDA) receptor/nitric oxide cascade. Many classes of NMDA receptor antagonists can effectively prevent or reverse morphine tolerance (Trujillo and Akil, 1991) , as can inhibition of nitric oxide synthase (Kolesnikov et al., 1997) . The importance of dispositional issues was established by studies on P-glycoprotein (King et al., 2001) . Chronic administration of morphine upregulates P-glycoprotein, which in turn decreases morphine penetration into the brain. Knocking out Pgp prevents morphine tolerance. Most recently, investigators have explored receptor trafficking (Von Zastrow, 2010) and suggested a role for m-opioid/d-opioid receptor (MOR/DOR) heterodimers (Gupta et al., 2010) . These various different mechanisms are not exclusive and all probably contribute to the overall response.
The role of d systems in morphine tolerance was first proposed by Takemori and coworkers (Abdelhamid et al., 1991) , who showed that the DOR antagonist naltrindole prevents morphine tolerance. The importance of DORs was confirmed by studies in DOR knockout mice and antisense downregulation models that also revealed the loss of morphine tolerance. In the current paper by He and coworkers (He et al., 2011) , the authors find that spinal delivery of the d ligand deltorphin I diminished morphine actions, consistent with an inhibitory modulation of morphine analgesia. The opioid field has long had controversies and data that appear contradictory, and the role of d systems in morphine action is no exception. Soon after their discovery, enkephalins, endogenous DOR ligands, were shown to be potent analgesics given either spinally or supraspinally. Furthermore, Porreca and coworkers (Porreca et al., 1987) demonstrated that d ligands given supraspinally, but not spinally, potentiated morphine analgesia in naive and tolerant mice. Thus, d drugs can both potentiate and diminish morphine analgesia. A number of potential explanations for these conflicting results are possible, including the site of action (i.e., spinal versus supraspinal), since potentiation was previously seen only supraspinally while the decreased effect in the current paper was documented at the spinal level.
